NCT06118294Withdrawn
Efficacy of Probiotics for Parkinson Disease (PD)
Source: ClinicalTrials.gov · Last updated 23 Apr 2024
Reason given: PI has retired
Brief summary (registry, in English)
In previous clinical studies, PS128 has been reported to ameliorate motor deficits in Parkinson's disease (PD). PS23 has been reported to delay some age-related disorders. On the basis of previous animal and clinical studies which hope that this study can support the theory of the gut-brain axis, and have the opportunity to realize the relationship between peripheral inflammation and neurodegeneration.
- Status (registry)
- Withdrawn
- Study type
- Interventional
- Enrollment
- 0 (actual)
- First submitted
- 31 Oct 2023
- Start date
- 8 Nov 2023
- Primary completion date
- 30 Oct 2026
- Lead sponsor
- Changhua Christian Hospital
- Diseases
- Parkinson disease
- NCT number
- NCT06118294
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Diagnosed before 40 years old.
Other
- Used probiotic products in powder, capsule, or tablet form within four weeks.
- Have taken antibiotics within four weeks.
- Those who are not suitable to participate in the research are judged by PI.
Who the study is looking for
- The age between 41-80 years old and at least the elementary education level.
- Diagnosed as a patient with Parkinson's disease of modified Hoehn and Yahr Stage between 1 and 3 as rated.
Age in the registry: 41 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Changhua Christian Hospital (CCH) | Changhua | Taiwan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.